Dorothy Halliday

4.2k total citations
32 papers, 819 citations indexed

About

Dorothy Halliday is a scholar working on Neurology, Epidemiology and Rheumatology. According to data from OpenAlex, Dorothy Halliday has authored 32 papers receiving a total of 819 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Neurology, 19 papers in Epidemiology and 7 papers in Rheumatology. Recurrent topics in Dorothy Halliday's work include Neurofibromatosis and Schwannoma Cases (21 papers), Meningioma and schwannoma management (19 papers) and Vascular Malformations Diagnosis and Treatment (10 papers). Dorothy Halliday is often cited by papers focused on Neurofibromatosis and Schwannoma Cases (21 papers), Meningioma and schwannoma management (19 papers) and Vascular Malformations Diagnosis and Treatment (10 papers). Dorothy Halliday collaborates with scholars based in United Kingdom, United States and Australia. Dorothy Halliday's co-authors include D. Gareth Evans, Allyson Parry, Pieter Pretorius, Sally Painter, Shazia Afridi, Samuel MacKeith, Miriam J. Smith, Patrick Axon, Andrew T. King and John F. Golding and has published in prestigious journals such as Journal of Applied Physics, Neurology and British Journal of Pharmacology.

In The Last Decade

Dorothy Halliday

32 papers receiving 798 citations

Peers

Dorothy Halliday

NEURO

EPIDE

GENET

RHEUM

Roope A. Kallionpää Finland

Said Farschtschi Germany

A. Vital France

David Bourn United Kingdom

Sam-Suk Kang South Korea

J. Viaño Spain

Omar Pathmanaban United Kingdom

Maria D’Souza India

Philippe Petiot France

G Giuliani Italy

Roope A. Kallionpää Finland

Dorothy Halliday

551 ×1.0

NEURO

196 ×0.5

EPIDE

103 ×0.7

54 ×0.5

GENET

187 ×1.6

RHEUM

Citations per year, relative to Dorothy Halliday Dorothy Halliday (= 1×) peers Roope A. Kallionpää

Countries citing papers authored by Dorothy Halliday

Since Specialization

Citations

This map shows the geographic impact of Dorothy Halliday's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dorothy Halliday with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dorothy Halliday more than expected).

Fields of papers citing papers by Dorothy Halliday

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dorothy Halliday. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dorothy Halliday. The network helps show where Dorothy Halliday may publish in the future.

Co-authorship network of co-authors of Dorothy Halliday

This figure shows the co-authorship network connecting the top 25 collaborators of Dorothy Halliday. A scholar is included among the top collaborators of Dorothy Halliday based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dorothy Halliday. Dorothy Halliday is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Smith, Miriam J., George J. Burghel, Sarah Waller, et al.. (2024). Genetic findings in people with schwannomas who do not meet clinical diagnostic criteria for NF2-related schwannomatosis. Journal of Medical Genetics. 61(11). 1011–1015. 2 indexed citations

Halliday, Dorothy, et al.. (2023). Updated protocol for genetic testing, screening and clinical management of individuals at risk of NF2 ‐related schwannomatosis. Clinical Genetics. 103(5). 540–552. 6 indexed citations

Halliday, Dorothy, et al.. (2023). Stereotactic Radiosurgery and Radiotherapy for Vestibular Schwannoma in NF2‐Related Schwannomatosis. The Laryngoscope. 134(5). 2364–2371. 1 indexed citations

Wasik, Martin, et al.. (2021). Structural Abnormalities of the Central Retina in Neurofibromatosis Type 2. Ophthalmic Research. 65(1). 77–85. 2 indexed citations

Bowers, Naomi L., Claire Hartley, Philip Smith, et al.. (2020). Sporadic vestibular schwannoma: a molecular testing summary. Journal of Medical Genetics. 58(4). 227–233. 13 indexed citations

Halliday, Dorothy, Grace Vassallo, Karine Lascelles, et al.. (2019). Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity. Clinical Genetics. 96(2). 151–162. 15 indexed citations

Painter, Sally, et al.. (2018). Neurofibromatosis Type 2–Related Eye Disease Correlated With Genetic Severity Type. Journal of Neuro-Ophthalmology. 39(1). 44–49. 19 indexed citations

Anand, Geetha, Michael Pike, Sanjay R. Mehta, et al.. (2018). Diagnosis of sporadic neurofibromatosis type 2 in the paediatric population. Archives of Disease in Childhood. 103(5). 463–469. 17 indexed citations

King, Andrew T., Scott Rutherford, Charlotte Hammerbeck-Ward, et al.. (2017). Malignant Peripheral Nerve Sheath Tumors are not a Feature of Neurofibromatosis Type 2 in the Unirradiated Patient. Neurosurgery. 83(1). 38–42. 20 indexed citations

10.

Morris, Katrina, John F. Golding, Patrick Axon, et al.. (2016). Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neuro-Oncology Practice. 3(4). 281–289. 59 indexed citations

11.

Morris, Katrina, John F. Golding, Claire Blesing, et al.. (2016). Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort. Journal of Neuro-Oncology. 131(1). 117–124. 40 indexed citations

12.

Jones, Adrian L., Harry Joe, Miriam J. Smith, et al.. (2015). Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. Journal of Medical Genetics. 52(10). 699–705. 63 indexed citations

13.

Ferner, Rosalie E., Adam Shaw, D. Gareth Evans, et al.. (2014). Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. Journal of Neurology. 261(5). 963–969. 36 indexed citations

14.

Smith, Miriam J., Christian Beetz, Simon G. Williams, et al.. (2014). Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis. Neurology. 84(2). 141–147. 78 indexed citations

15.

Smith, Miriam J., Jenny Higgs, Naomi L. Bowers, et al.. (2011). Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset. Journal of Medical Genetics. 48(4). 261–265. 84 indexed citations

16.

Evans, D. Gareth, et al.. (2011). Genetic testing and screening of individuals at risk of NF2. Clinical Genetics. 82(5). 416–424. 39 indexed citations

17.

Absoud, Michael, Jeremy Parr, Dorothy Halliday, et al.. (2009). A novel ARX phenotype: rapid neurodegeneration with Ohtahara syndrome and a dyskinetic movement disorder. Developmental Medicine & Child Neurology. 52(3). 305–307. 33 indexed citations

18.

Mátyás, Gábor, Anne De Paepe, Dorothy Halliday, et al.. (2002). Evaluation and application of denaturing HPLC for mutation detection in Marfan syndrome: Identification of 20 novel mutations and two novel polymorphisms in theFBN1gene. Human Mutation. 19(4). 443–456. 57 indexed citations

19.

Wordsworth, B P & Dorothy Halliday. (2001). The real connective tissue diseases. Clinical Medicine. 1(1). 21–24. 1 indexed citations

20.

Halliday, Dorothy, Sarah Hutchinson, Susan Kettle, et al.. (1999). Molecular analysis of eight mutations in FBN1. Human Genetics. 105(6). 587–597. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact